1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
"Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R61/R33 Clinical Trial Required)" is currently closed and not accepting applications.
Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R61/R33 Clinical Trial Required) is sponsored by National Institute of Mental Health (NIMH). Funds development of psychosocial interventions for mental disorders, including personality disorders.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R61/R33 Clinical Trial Required) | Research Funding National Institutes of Health Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R61/R33 Clinical Trial Required) The purpose of this NOFO is to encourage pilot research developing and testing innovative psychosocial intervention approaches in which the target and/or intervention strategy is novel.
Consistent with NIMH’s experimental therapeutics approach, this NOFO is intended to speed the translation of emergent research on mechanisms and processes underlying mental disorders into promising novel psychosocial preventative or therapeutic interventions.
Targets may include, but are not limited to, potentially modifiable behavioral, cognitive, affective, and/or interpersonal factors or processes, neural circuits or neural activity subserving specific behaviors or cognitive processes, and/or other neurobiological mechanisms.
Novel psychosocial interventions may be standalone interventions or novel augmentations to efficacious interventions for which there is an empirical rationale by which the augmentation (and corresponding target) is expected to substantially enhance outcomes.
Support will be provided for up to two years (R61 phase) for preliminary milestone-driven testing of a novel intervention's impact on a target process or mechanism associated with mental disorder risk, causation, or maintenance (target engagement). Up to 3 years of additional support (R33 phase) will be provided for studies with findings that meet the "go/no-go" milestones embedded in the R61 phase.
The R33 phase is intended to support the replication of target engagement and to test whether engaging the intervention target/mechanism mediates changes in clinical outcomes. Ultimately, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support "go/no-go" decisions about further development and/or testing of the intervention.
Applicants pursuing other stages of the clinical trial pipeline should consider one of the companion NOFOs listed above.
Letter of Intent Due Date(s): 30 days before the application due date Application Due Date(s): Feb 14, 2025; June 17, 2025; Oct 15, 2025; Feb 13, 2026; June 15, 2026; Oct 15, 2026; Feb 17, 2027; June 15, 2027; Oct 15, 2027 PAR-25-182 Expiration Date October 16, 2027 The scope of the proposed project should determine the project period.
The maximum period of the combined R61 and R33 phases is 5 years, with up to 2 years for the R61 phase and up to 3 years for the R33 phase. Applications with a project period less than 5 years are encouraged where feasible. Medical - Clinical Science
According to the current listing, eligibility includes: Universities, Nonprofits, For-profits, State/local governments, and others. Confirm the full requirements in the official notice before applying.
The current listing shows up to $275,000 over two years. Verify award ceilings, matching requirements, and allowable costs in the official notice.
The published deadline was March 31, 2025, which has passed. Check the official notice for any future application windows before investing time in a proposal.
Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R61/R33 Clinical Trial Required) is funded by National Institute of Mental Health (NIMH). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
PMHCA (HRSA-26-058) makes $9.79 million available for up to 22 awards of up to $445,000 to build tele-consultation networks that help pediatric primary care providers manage children's behavioral health. The catch buried in the eligibility section: applicants must NOT already hold a PMHCA award — which effectively reserves the new-state lane for the eight unfunded states and territories, plus tribes everywhere. Here's how to read it and what wins.
Read articleTennessee's $206.9M RHTP allocation begins distribution with a 30-day virtual maternal/child mental health consultation grant. The state plans a new opportunity every Friday — the cadence and structure here are the blueprint for how the $50B nationwide program rolls out.
Read articleThe April 18 executive order, ARPA-H EVIDENT initiative, and FDA priority vouchers are reshaping mental health research funding. A guide for grant seekers.
Read article